<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120229//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.2.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art520.dtd?><?SourceDTD.Version 5.2.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 2?><?origin publisher?><?FILEmeta_CUTHRE461 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Ther Res Clin Exp</journal-id><journal-id journal-id-type="iso-abbrev">Curr Ther Res Clin Exp</journal-id><journal-title-group><journal-title>Current Therapeutic Research, Clinical and Experimental</journal-title></journal-title-group><issn pub-type="ppub">0011-393X</issn><issn pub-type="epub">1879-0313</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4266770</article-id><article-id pub-id-type="publisher-id">S0011-393X(14)00019-8</article-id><article-id pub-id-type="doi">10.1016/j.curtheres.2014.08.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Efficacy and Safety of Celecoxib in Chinese Patients with Ankylosing Spondylitis: A 6-Week Randomized, Double-Blinded Study with 6-Week Open-Label Extension Treatment </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Feng</given-names></name><degrees>MD</degrees><email>fhuang1964@yahoo.com</email><xref rid="aff0005" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Jieruo</given-names></name><degrees>MD</degrees><xref rid="aff0010" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yi</given-names></name><degrees>MD</degrees><xref rid="aff0015" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Ping</given-names></name><degrees>MD</degrees><xref rid="aff0020" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Yi</given-names></name><degrees>MD</degrees><xref rid="aff0025" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Jin</given-names></name><degrees>MD</degrees><xref rid="aff0030" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Sharon</given-names></name><degrees>PhD</degrees><xref rid="aff0035" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Le</surname><given-names>Shi</given-names></name><degrees>MD</degrees><xref rid="aff0040" ref-type="aff">8</xref></contrib></contrib-group><aff id="aff0005"><label>1</label>Department of Rheumatology, Chinese PLA General Hospital, Beijing, China</aff><aff id="aff0010"><label>2</label>Department of Rheumatology and Immunology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China</aff><aff id="aff0015"><label>3</label>Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Sichuan, China</aff><aff id="aff0020"><label>4</label>Department of Rheumatology and Immunology, Xijing Hospital, Shanxi, China</aff><aff id="aff0025"><label>5</label>Department of Rheumatology and Immunology, Beijing Chaoyang Hospital, Capital University of Medical Science, Beijing, China</aff><aff id="aff0030"><label>6</label>Clinical Program Lead, Global Innovation Pharma, Clinical Science, Pfizer Investment Co, Ltd, Beijing, China</aff><aff id="aff0035"><label>7</label>Emerging Markets Business Unit, Pfizer Inc, New York, NY</aff><aff id="aff0040"><label>8</label>Former employee of Department of Clinical Development and Operation (China), Pfizer Investment Co, Ltd, Beijing, China</aff><author-notes><corresp id="cor1"><label>⁎</label>Address correspondence to: Feng Huang, MD, Department of Rheumatology, Chinese PLA General Hospital, 28 Fuxing Rd, Beijing 100853, China. <email>fhuang1964@yahoo.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>5</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2014</year></pub-date><volume>76</volume><fpage>126</fpage><lpage>133</lpage><history><date date-type="accepted"><day>19</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 The Authors</copyright-statement><copyright-year>2014</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).</license-p></license></permissions><abstract><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Nonsteroidal anti-inflammatory drugs are the first-line option for treating ankylosing spondylitis (AS) in China. </plain></SENT>
<SENT sid="3" pm="."><plain>However, no large-scale controlled trials have been conducted in this ethnic population. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="4" pm="."><plain>Objective </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>To evaluate the efficacy and safety of 6 weeks’ treatment with celecoxib in patients with AS in China. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="6" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>This Phase 3, double-blind, parallel-group study randomized patients with AS aged ≥18 to 65 years 1:1 to receive celecoxib 200 mg once daily or diclofenac sustained release 75 mg once daily. </plain></SENT>
<SENT sid="8" pm="."><plain>After 6 weeks, patients could use celecoxib 400 mg once daily or maintain blinded therapy. </plain></SENT>
<SENT sid="9" pm="."><plain>The primary efficacy end point was mean change from baseline at Week 6 for Patient’s Global Assessment of Pain Intensity score (100-mm visual analog scale). </plain></SENT>
<SENT sid="10" pm="."><plain>Noninferiority was established if the upper bound of the CI was &lt;10 mm. </plain></SENT>
<SENT sid="11" pm="."><plain>Secondary objectives included patients’ and physicians’ assessments of disease activity, change from baseline in C-reactive protein level, and safety. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="12" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>In the per-protocol analysis set the least squares mean change from baseline in the Patient’s Global Assessment of Pain Intensity score at Week 6 was –23.8 mm and –27.1 mm in patients receiving celecoxib (n = 111) and diclofenac (n = 108), respectively. </plain></SENT>
<SENT sid="14" pm="."><plain>The 2-sided 95% CI for the treatment difference (celecoxib – diclofenac) was –2.2 to 8.8. </plain></SENT>
<SENT sid="15" pm="."><plain>Overall, 4.2% and 6.7% of patients in the celecoxib and diclofenac groups, respectively, reported treatment-related adverse events. </plain></SENT>
<SENT sid="16" pm="."><plain>All were mild to moderate in severity. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="17" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="18" pm="."><plain>Celecoxib 200 mg once daily is noninferior to diclofenac sustained release 75 mg once daily for pain treatment in Chinese patients with AS. </plain></SENT>
<SENT sid="19" pm="."><plain>ClinicalTrials.gov identifier: NCT00762463. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group><title>Key words</title><kwd>ankylosing spondylitis</kwd><kwd>COX-2 inhibitors</kwd><kwd>musculoskeletal system</kwd><kwd>nonsteroidal anti-inflammatory drugs</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="s0005"><title><text><SENT sid="20" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="21" pm="."><plain>Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton manifested by inflammatory back pain, progressive stiffness of the spine, arthritis, enthesitis, and acute anterior uveitis.1,2 Symptoms of AS traditionally appear during late adolescence and early adulthood, and the condition is a significant health burden in young male adults.3 If the disease is undiagnosed or inadequately treated, patients with AS may experience continuous pain, stiffness, fatigue, and a progressive loss of spinal mobility and function, which ultimately leads to a reduction in quality of life.4 The 1984 modified New York criteria describe the classification criteria for AS.5 Patients may be diagnosed with AS if characteristic radiologic changes of the sacroiliac joint are present, together with defined clinical symptoms and physical findings. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Nonsteroidal anti-inflammatory drugs (NSAIDs) are currently the mainstay of treatment for AS.6 In China, where the prevalence of AS is 0.3%,7 nonselective (ns) NSAIDs and tumor necrosis factor-α (TNFα) antagonists are approved AS treatments. </plain></SENT>
<SENT sid="23" pm="."><plain>In addition, a number of other medications, including disease-modifying antirheumatic drugs, opioids, and muscle relaxants are prescribed for the treatment of patients with AS.7 However, evidence suggests that, particularly over the longer term, the use of nsNSAIDs and injectable TNFα antagonists may be limited by the concern for adverse events (AEs) and other undesirable effects.8,9 The use of nsNSAIDs has been associated with AEs affecting the gastrointestinal (GI) tract8 and cardiovascular system,10–13 with diclofenac being associated with a particularly high risk of cardiovascular adverse events.11 In addition, nsNSAIDs are also believed to exacerbate inflammatory bowel disease that often accompanies spondyloarthropathies.14–18 Although injectable TNFα antagonists have been shown to be effective treatments for the signs and symptoms of AS,19,20 the cost of use, inconvenience of administration, and possible safety concerns9 may limit their use to refractory or severe cases. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>Compared with nsNSAIDs, which inhibit both cyclooxygenase (COX)-1 and COX-2, the COX-2 selective NSAIDs are thought to have a superior GI safety profile21 because they selectively inhibit COX-2–mediated production of inflammatory mediators while preserving the integrity of the gastroduodenal mucosa (through COX-1 mediated synthesis of prostanoids).22 Furthermore, the rate of cardiovascular AEs has been demonstrated to be comparable to that of nsNSAIDs in a meta-analysis.23 </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>Outside of China, the COX-2 selective NSAID celecoxib has been evaluated in 2 double-blind, randomized, controlled, active-comparator trials in patients with AS.24,25 However, to date, no large-scale randomized controlled trials have been conducted in China, where there is a paucity of efficacy and safety data for this treatment. </plain></SENT>
<SENT sid="26" pm="."><plain>Therefore the primary objective of our study was to demonstrate noninferiority of celecoxib 200 mg once daily compared with diclofenac sustained release (SR) 75 mg once daily in the treatment of Chinese patients with AS in terms of pain assessment after 6 weeks of treatment. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="s0010"><title><text><SENT sid="27" pm="."><plain>Patients and Methods </plain></SENT>
</text></title><sec id="s0015"><title><text><SENT sid="28" pm="."><plain>Study design </plain></SENT>
</text></title><p><text><SENT sid="29" pm="."><plain>Our study (ClinicalTrials.gov identifier NCT00762463) was a randomized, active-comparator, double-blind, parallel-group, noninferiority study conducted at 5 centers across China. </plain></SENT>
<SENT sid="30" pm="."><plain>The protocol was approved by the institutional review board or independent ethics committee at each center, and the study was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonisation guidelines for Good Clinical Practice, and local regulatory requirements. </plain></SENT>
<SENT sid="31" pm="."><plain>The study consisted of a double-blind treatment period lasting 6 weeks, followed by a 6-week extension period. </plain></SENT>
<SENT sid="32" pm="."><plain>All patients provided written informed consent before any screening procedures were performed. </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>The study included a total of 6 study visits: screening visit (Visit 1), baseline visit (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), and Week 12 (Visit 6 for those enrolled in the extension period) or when the study drug was terminated (end-of-treatment visit) (Figure 1). </plain></SENT>
<SENT sid="34" pm="."><plain>However, unscheduled visits were possible at any time during the study treatment if required. </plain></SENT>
</text></p><p><text><SENT sid="35" pm="."><plain>The primary objective was to demonstrate noninferiority of celecoxib 200 mg once daily compared with diclofenac SR 75 mg once daily in the treatment of patients with AS in the per-protocol analysis set population, in terms of their pain assessment at Week 6. </plain></SENT>
<SENT sid="36" pm="."><plain>Diclofenac was chosen as the active comparator in this study because it is commonly used to treat AS.26 A dose of 75 mg diclofenac SR once daily was chosen to minimize the emergence of AEs that have been associated with the higher dose of 150 mg daily.27,28 </plain></SENT>
</text></p></sec><sec id="s0020"><title><text><SENT sid="37" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="38" pm="."><plain>Adult male and female patients aged 18 to 65 years were eligible for inclusion if they had AS according to the 1984 modified New York criteria for classification of AS.5 In addition, all patients must have had a diagnosis of AS with axial involvement but without peripheral joint involvement (synovitis) at the time of study entry. </plain></SENT>
<SENT sid="39" pm="."><plain>Patients were required to have been receiving daily treatment with NSAIDs 30 days before study entry. </plain></SENT>
<SENT sid="40" pm="."><plain>Patients were excluded if they had known inflammatory enteropathy, the presence of other extra-articular manifestations, known vertebral compression, or the need to wear a corset during the study. </plain></SENT>
<SENT sid="41" pm="."><plain>In addition, patients were excluded if they required the use of concomitant muscle relaxants, hypnotics, anxiolytics, sedatives, tranquillizers, or antidepressant drugs, or the concomitant use of anticoagulants, ticlopidine, lithium, aspirin &gt;150 mg/d, methotrexate &gt;15 mg/wk, prednisolone &gt;10 mg/d (or equivalent dose of other corticosteroids), NSAIDs, or COX-2 inhibitors (other than study drug or biologics). </plain></SENT>
<SENT sid="42" pm="."><plain>Women with childbearing potential were required to have been using adequate contraception. </plain></SENT>
</text></p></sec><sec id="s0025"><title><text><SENT sid="43" pm="."><plain>Treatment </plain></SENT>
</text></title><p><text><SENT sid="44" pm="."><plain>Patients were randomized 1:1 to receive either celecoxib 200 mg once daily or diclofenac SR 75 mg once daily for 6 weeks (Figure 1). </plain></SENT>
<SENT sid="45" pm="."><plain>Randomization was performed using a computer-generated schedule that generated a random permuted-blocks design. </plain></SENT>
<SENT sid="46" pm="."><plain>Each patient qualifying for a treatment assignment was given the next consecutive number within a center and was dispensed the corresponding study medication. </plain></SENT>
<SENT sid="47" pm="."><plain>To ensure that the treatment remained blinded to the investigators and patients during the double-blind period, a double-dummy method of blinding was used (celecoxib 200 mg capsules, diclofenac SR 75 mg tablets, and their respective matching placebos were similar in size, color, smell, taste, and appearance). </plain></SENT>
<SENT sid="48" pm="."><plain>Rescue medication in the form of acetaminophen/paracetamol could be taken on demand, but the dose could not exceed a total daily dose of 2 g. </plain></SENT>
</text></p><p><text><SENT sid="49" pm="."><plain>All patients who exhibited no study medication-related AEs were offered extension treatment at the end of the 6-week, double-blind period; patients in the celecoxib 200 mg once daily (C200) and diclofenac SR 75 mg once daily (D75) groups received either open-label celecoxib 400 mg once daily (herein referred to as the C200/C400 or D75/C400 group) or continuation of their double-blind period therapies (herein referred to as the C200 or D75 no treatment change [NTC] groups) for an additional 6 weeks. </plain></SENT>
<SENT sid="50" pm="."><plain>In the extension phase, assignment to celecoxib 400 mg once daily was open to the investigators, patients, and the sponsor’s study team. </plain></SENT>
<SENT sid="51" pm="."><plain>Patients who maintained their celecoxib 200 mg once daily or diclofenac SR 75 mg once daily therapies were dispensed medication in the same manner they had received medication during the double-blind phase. </plain></SENT>
<SENT sid="52" pm="."><plain>These patients remained blinded to the study medication assignments. </plain></SENT>
<SENT sid="53" pm="."><plain>Dose adjustments were not permitted during the study and extension period. </plain></SENT>
</text></p></sec><sec id="s0030"><title><text><SENT sid="54" pm="."><plain>Efficacy evaluations </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>The primary end point was the mean change from baseline at Week 6 during the double-blind treatment period in the Patient’s Global Assessment of Pain Intensity score. </plain></SENT>
<SENT sid="56" pm="."><plain>The Patient’s Global Assessment of Pain Intensity score was based on a 100-mm visual analog scale (VAS) pain scale where 0 = no pain and 100 = worst possible pain. </plain></SENT>
<SENT sid="57" pm="."><plain>The secondary end points were the change from baseline at Weeks 2, 4, and 6 in the Patient’s Global Assessment of Pain Intensity score, the Patient’s Global Assessment of Disease Activity score (measured on a 5-point Likert scale where 1 = very good and 5 = very poor), the Physician’s Global Assessment of Disease Activity score (measured on a 5-point Likert scale where 1 = very good and 5 = very poor), the Bath Ankylosing Spondylitis Functional Index score (comprising a series of 10 specific questions, each answered on a 100-mm VAS where 0 = easy and 100 = impossible), the Bath Ankylosing Spondylitis Disease Activity Index score (comprising a series of 6 questions), nocturnal pain, the distance from fingertips to floor (measured in centimeters), chest expansion (measured in centimeters), Assessment in Ankylosing Spondylitis (ASAS-20) score, and measures of the change from baseline at Week 6 in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level. </plain></SENT>
</text></p></sec><sec id="s0035"><title><text><SENT sid="58" pm="."><plain>Safety evaluations </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>Safety evaluations included monitoring of AEs, treatment discontinuations, and the use of concomitant medications, measurement of vital signs, a physical examination, and the assessment of clinical laboratory investigations. </plain></SENT>
<SENT sid="60" pm="."><plain>The specific laboratory assessments included hematology measurements, urine tests, and clinical chemistry measurements. </plain></SENT>
</text></p></sec><sec id="s0040"><title><text><SENT sid="61" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="62" pm="."><plain>SAS (version 9.0, SAS Institute Inc, Cary, North Carolina) was used for all analyses. </plain></SENT>
<SENT sid="63" pm="."><plain>The sample size calculation for this study was based on the primary end point, the Patient’s Global Assessment of Pain Intensity score at Week 6, and the hypothesis that celecoxib 200 mg once daily was noninferior to diclofenac SR 75 mg once daily. </plain></SENT>
<SENT sid="64" pm="."><plain>Based on the following assumptions, the noninferiority margin was 10 mm, the SD of pain intensity change from baseline at Week 6 was no more than 25 mm (based on Week 6 data from previously published25 and, as yet unpublished [COXA-0506-247], studies), and the power and significance level for the noninferiority test were 80% and 0.025 (1-sided), respectively, a sample size of 100 patients per-protocol analysis set in each treatment group was required. </plain></SENT>
<SENT sid="65" pm="."><plain>The noninferiority margin was selected a priori. </plain></SENT>
</text></p><p><text><SENT sid="66" pm="."><plain>The primary efficacy analysis was performed on the per-protocol analysis set, which comprised all randomized and treated patients who had a global pain intensity assessment at Week 6 and had no major protocol deviations during the 6-week, double-blind period. </plain></SENT>
<SENT sid="67" pm="."><plain>The primary end point was analyzed using analysis of covariance with treatment group and study center as factors and the baseline Patient’s Global Assessment of Pain Intensity score as a covariate. </plain></SENT>
<SENT sid="68" pm="."><plain>A 2-sided 95% CI was constructed for the least squares (LS) mean difference on the primary end point between celecoxib 200 mg once daily and diclofenac SR 75 mg once daily. </plain></SENT>
<SENT sid="69" pm="."><plain>Noninferiority was declared if the upper bound of the 95% CI was &lt;10 mm. </plain></SENT>
</text></p><p><text><SENT sid="70" pm="."><plain>All secondary efficacy end point analyses were performed on the full analysis set, which comprised all randomized patients who received at least 1 dose of study treatment. </plain></SENT>
</text></p><p><text><SENT sid="71" pm="."><plain>Safety analyses were performed on all randomized patients who received at least 1 dose of study medication. </plain></SENT>
<SENT sid="72" pm="."><plain>For the extension period the efficacy and safety analyses were analyzed separately. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s0045"><title><text><SENT sid="73" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s0050"><title><text><SENT sid="74" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="75" pm="."><plain>Overall, 255 patients were screened, of which 240 patients were randomized and received treatment (Figure 2). </plain></SENT>
<SENT sid="76" pm="."><plain>In total, 240 patients were included in the full analysis set, and 219 were included in the per-protocol analysis set for the efficacy analyses during the 6-week double-blind treatment phase. </plain></SENT>
</text></p><p><text><SENT sid="77" pm="."><plain>A total of 218 patients entered the extension period, of which 6 withdrew from the celecoxib 400 mg once daily group (4 in the C200/C400 group and 2 in the D75/C400 group). </plain></SENT>
<SENT sid="78" pm="."><plain>Of patients in the NTC population, 3 withdrew from the C200 NTC group, and 1 withdrew from the D75 NTC group. </plain></SENT>
</text></p><p><text><SENT sid="79" pm="."><plain>At baseline, 85.8% of patients (206 out of 240) were male. </plain></SENT>
<SENT sid="80" pm="."><plain>Other baseline characteristics were similar between the 2 treatment groups (Table I). </plain></SENT>
<SENT sid="81" pm="."><plain>In terms of prior NSAID use, 36.7% of patients (44 out of 120) in the celecoxib 200 mg once daily and 35.0% (42 out of 120) in the diclofenac SR 75 mg once daily groups were receiving either diclofenac or diclofenac sodium before the start of the study. </plain></SENT>
</text></p></sec><sec id="s0055"><title><text><SENT sid="82" pm="."><plain>Efficacy </plain></SENT>
</text></title><sec id="s0060"><title><text><SENT sid="83" pm="."><plain>Patient’s Global Assessment of Pain Intensity </plain></SENT>
</text></title><p><text><SENT sid="84" pm="."><plain>For the primary end point in the per protocol analysis set, the LS mean change from baseline in the Patient’s Global Assessment of Pain Intensity score (using a VAS) at Week 6 (per-protocol analysis set; Week 6 – baseline) was –23.8 mm and –27.1 mm in the celecoxib 200 mg once daily and diclofenac SR 75 mg once daily groups, respectively (Figure 3). </plain></SENT>
<SENT sid="85" pm="."><plain>The treatment difference (celecoxib – diclofenac SR) at Week 6 in the per-protocol analysis set was 3.3 mm and the 2-sided 95% CI for the treatment difference was (–2.2 to 8.8 mm). </plain></SENT>
<SENT sid="86" pm="."><plain>Because the upper bound of the 95% CI was &lt;10 mm, celecoxib was noninferior to diclofenac in the treatment of Chinese patients with AS. </plain></SENT>
</text></p><p><text><SENT sid="87" pm="."><plain>At the end of the extension phase (Week 12), the mean change from baseline was –28.4 mm in the C200 group and –30.9 mm in the D75 group. </plain></SENT>
<SENT sid="88" pm="."><plain>The treatment effect achieved by both treatment groups at the end of the 6-week double-blind period was maintained through Week 12. </plain></SENT>
</text></p><p><text><SENT sid="89" pm="."><plain>The Patient’s Global Assessment of Pain Intensity scores at Weeks 2, 4, and 6 for the full analysis set are summarized in Table II. </plain></SENT>
</text></p></sec><sec id="s0065"><title><text><SENT sid="90" pm="."><plain>Patient’s Global Assessment of Disease Activity </plain></SENT>
</text></title><p><text><SENT sid="91" pm="."><plain>The Patient’s Global Assessment of Disease Activity scores at Weeks 2, 4, and 6 are summarized in Table III. </plain></SENT>
<SENT sid="92" pm="."><plain>At the end of the extension phase (Week 12), the mean (SD) change from baseline was –0.6 (1.0) in the celecoxib group and –0.6 (0.8) in the diclofenac SR group. </plain></SENT>
<SENT sid="93" pm="."><plain>In patients who changed treatment during the extension period, the mean change from baseline at Week 6 in the C200/C400 group was noticeably smaller than in the C200 group. </plain></SENT>
<SENT sid="94" pm="."><plain>At Week 12 there was an improvement from Week 6 in the mean change from baseline in the C200/C400 group (–0.1 [0.7] at Week 6 vs –0.4 [0.7] at Week 12) and in the D75/C400 group (–0.4 [0.7] at Week 6 vs –0.6 [1.0] at Week 12). </plain></SENT>
</text></p></sec><sec id="s0070"><title><text><SENT sid="95" pm="."><plain>Physician’s Global Assessment of Disease Activity </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>The Physician’s Global Assessment of Disease Activity scores at Weeks 2, 4 and 6 are summarized in Table IV. </plain></SENT>
<SENT sid="97" pm="."><plain>At the end of the extension phase (Week 12), the mean (SD) change from baseline was –0.7 (0.6) in the C200 group and –0.5 (0.6) in the D75 group. </plain></SENT>
<SENT sid="98" pm="."><plain>At Week 12 there was an improvement from Week 6 in the mean change from baseline in the C200/C400 group (–0.2 [0.6] at Week 6 vs –0.5 [0.5] at Week 12) and in the D75/C400 group (–0.5 [0.7] at Week 6 vs –0.7 [0.8] at Week 12). </plain></SENT>
</text></p></sec><sec id="s0075"><title><text><SENT sid="99" pm="."><plain>Bath Ankylosing Spondylitis Functional Index </plain></SENT>
</text></title><p><text><SENT sid="100" pm="."><plain>The LS mean (SE) change from baseline at Week 6 in Bath Ankylosing Spondylitis Functional Index score was –0.5 (0.2) and –0.8 (0.2) in the celecoxib and diclofenac SR groups, respectively (treatment difference and 2-sided 95% CI; 0.3 [–0.1 to 0.7]). </plain></SENT>
<SENT sid="101" pm="."><plain>At Week 12, the mean change from baseline was –0.9 (1.8) in the C200 group and –1.0 (1.6) in the D75 group. </plain></SENT>
<SENT sid="102" pm="."><plain>In patients who changed treatment during the extension period, the mean change from baseline at Week 6 in the C200/C400 group was noticeably smaller than in the C200 group. </plain></SENT>
<SENT sid="103" pm="."><plain>At Week 12, there was an improvement from Week 6 in the mean change from baseline in the C200/C400 group (–0.2 [1.8] at Week 6 vs –0.6 [2.0] at Week 12) and in the D75/C400 group (–0.8 [2.1] at Week 6 vs –1.0 [2.3] at Week 12). </plain></SENT>
</text></p></sec><sec id="s0080"><title><text><SENT sid="104" pm="."><plain>Bath Ankylosing Spondylitis Disease Activity Index </plain></SENT>
</text></title><p><text><SENT sid="105" pm="."><plain>The LS mean (SE) change from baseline at Week 6 in Bath Ankylosing Spondylitis Disease Activity Index was –1.1 (0.2) in the celecoxib group and –1.4 (0.2) in the diclofenac SR group (treatment difference = 0.3; 2-sided 95% CI, –0.1 to 0.8). </plain></SENT>
<SENT sid="106" pm="."><plain>At Week 12, the mean change from baseline was –1.7 (1.9) in the C200 group and –2.1 (1.9) in the D75 group. </plain></SENT>
<SENT sid="107" pm="."><plain>In patients who changed treatment during the extension period, the mean change from baseline at Week 6 in the C200/C400 group was noticeably smaller than in the C200 group. </plain></SENT>
<SENT sid="108" pm="."><plain>At Week 12, the change in baseline in the C200/C400 group was maintained (–0.6 [1.6] at Week 6 vs –0.6 [1.9] at Week 12) and in the D75/C400 group (–1.3 [2.1] at Week 6 vs –1.4 [2.1] at Week 12). </plain></SENT>
</text></p></sec><sec id="s0085"><title><text><SENT sid="109" pm="."><plain>ASAS-20 responders </plain></SENT>
</text></title><p><text><SENT sid="110" pm="."><plain>The percentage of ASAS-20 responders at Week 6 was 30.2% in the celecoxib group and 34.2% in the diclofenac SR group (Table V). </plain></SENT>
<SENT sid="111" pm="."><plain>The 2-sided 95% CI for the treatment difference was (–16.5 to 7.9). </plain></SENT>
<SENT sid="112" pm="."><plain>At the end of the extension phase (Week 12), the percentage of ASAS-20 responders was 49.0% in the C200 group and 47.2% in the D75 group. </plain></SENT>
</text></p></sec><sec id="s0090"><title><text><SENT sid="113" pm="."><plain>ESR and CRP </plain></SENT>
</text></title><p><text><SENT sid="114" pm="."><plain>The LS mean (SE) change from baseline at Week 6 in ESR was –2.5 (1.3) mm/h in the celecoxib group and –1.8 (1.3) mm/h in the diclofenac SR group (treatment difference and 2-sided 95% CI; –0.7 mm/h [–4.3 to 2.9 mm/h]). </plain></SENT>
<SENT sid="115" pm="."><plain>At Week 12, the mean (SD) change from baseline was –3.5 (14.0) mm/h in the C200 group and –1.3 (11.1) mm/h in the D75 group. </plain></SENT>
<SENT sid="116" pm="."><plain>In patients who changed treatment during the extension period, the mean (SD) change from baseline at Week 12 was –6.3 (13.5) mm/h in the C200/C400 group and –0.7 (19.5) mm/h in the D75/C400 group. </plain></SENT>
<SENT sid="117" pm="."><plain>For CRP, the LS mean (SE) change from baseline at Week 6 was –4.2 (1.6) mg/L in the celecoxib group and –2.7 (1.6) mg/L in the diclofenac SR group (treatment difference and 2-sided 95% CI; –1.4 mg/L [–5.8 to 2.9 mg/L]). </plain></SENT>
<SENT sid="118" pm="."><plain>At Week 12, the mean (SD) change from baseline was –4.6 (9.7) mg/L in the C200 group and –3.0 (13.2) mg/L in the D75 group. </plain></SENT>
<SENT sid="119" pm="."><plain>In patients who changed treatment during the extension period, the mean (SD) change from baseline at Week 12 was –4.8 (24.7) mg/L in the C200/C400 group and –2.1 (20.9) mg/L in the D75/C400 group. </plain></SENT>
</text></p></sec><sec id="s0095"><title><text><SENT sid="120" pm="."><plain>Nocturnal pain, fingertips to floor distance, and chest expansion </plain></SENT>
</text></title><p><text><SENT sid="121" pm="."><plain>The LS mean (SE) change from baseline at Week 6 in nocturnal pain was –15.4 (2.0) and –19.4 (2.0) in the celecoxib and diclofenac SR groups, respectively (treatment difference and 2-sided 95% CI; 4.0 [–1.4 to 9.5]). </plain></SENT>
<SENT sid="122" pm="."><plain>At Week 12, the mean change from baseline was –19.4 (22.5) in the C200 group and –27.5 (25.6) in the D75 group. </plain></SENT>
</text></p><p><text><SENT sid="123" pm="."><plain>The LS mean (SE) change in fingertips to floor distance from baseline at Week 6 was –2.8 (0.7) and –3.1 (0.7) in the celecoxib and diclofenac SR groups, respectively. </plain></SENT>
<SENT sid="124" pm="."><plain>At Week 12, the mean (SD) change from baseline was –3.0 (9.4) cm in the C200 group and –3.7 (6.8) cm in the D75 group. </plain></SENT>
<SENT sid="125" pm="."><plain>The mean (SD) change from baseline at Week 12 was –2.2 (8.0) in the C400 group. </plain></SENT>
</text></p><p><text><SENT sid="126" pm="."><plain>The LS mean (SE) change from baseline at Week 6 in chest expansion was 0.7 (0.1) in the celecoxib group and 0.6 (0.1) in the diclofenac SR group. </plain></SENT>
<SENT sid="127" pm="."><plain>At Week 12, the mean change from baseline was 0.8 (1.3) cm in the C200 group and 0.8 (1.4) cm in the D75 group. </plain></SENT>
<SENT sid="128" pm="."><plain>The mean change from baseline at Week 12 was 0.8 (1.2) cm in the C400 group. </plain></SENT>
</text></p></sec></sec><sec id="s0100"><title><text><SENT sid="129" pm="."><plain>Safety profile </plain></SENT>
</text></title><p><text><SENT sid="130" pm="."><plain>AEs occurring in both treatment phases by patient treatment group are summarized in Table VI. </plain></SENT>
<SENT sid="131" pm="."><plain>All were mild to moderate in intensity; no serious AEs or deaths were reported during our study. </plain></SENT>
<SENT sid="132" pm="."><plain>There were no clinically significant changes in vital signs during the double-blind period and 6-week extension period in any of the treatment groups. </plain></SENT>
<SENT sid="133" pm="."><plain>During the double-blind period, rescue medication in the form of acetaminophen/paracetamol was taken by 3 patients in the celecoxib 200 mg once daily group and 0 patients in the diclofenac SR 75 mg once daily group. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s0105"><title><text><SENT sid="134" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="135" pm="."><plain>Effective treatment of AS should meet the following 3 goals: relief of back pain and stiffness, reduction of the underlying inflammation, and improvement in physical function. </plain></SENT>
<SENT sid="136" pm="."><plain>Although NSAIDs are widely used in the treatment of AS, a number of safety and tolerability concerns surrounding their use (particularly over the longer term) still exist. </plain></SENT>
<SENT sid="137" pm="."><plain>Meanwhile, data supporting the use of alternative therapeutic options, such as COX-2 selective NSAIDs, are lacking. </plain></SENT>
<SENT sid="138" pm="."><plain>In the absence of direct head-to-head comparisons between COX-2 selective and nonselective NSAIDs in China, the present study was conducted. </plain></SENT>
<SENT sid="139" pm="."><plain>Diclofenac SR was selected as the active control because it is widely used by patients who have AS.26 The double-blind treatment duration of 6 weeks was chosen because celecoxib has been shown to be statistically superior to placebo in placebo-controlled clinical studies of 6 to 12 weeks’ duration in patients with AS.24,25 Using the ASAS-20 response criteria, no changes in the response rates at Week 12 compared with Week 6 were demonstrated. </plain></SENT>
<SENT sid="140" pm="."><plain>A 6-week extension was also conducted to observe the safety profile and to collect efficacy data for celecoxib 400 mg in Chinese patients. </plain></SENT>
</text></p><p><text><SENT sid="141" pm="."><plain>Our study demonstrated that celecoxib 200 mg once daily was noninferior to diclofenac SR 75 mg once daily in the treatment of Chinese patients with AS. </plain></SENT>
<SENT sid="142" pm="."><plain>In addition, patients in the celecoxib 200 mg once daily group experienced similar improvements in pain relief, disease activity, and physical function compared with patients receiving diclofenac SR 75 mg once daily. </plain></SENT>
<SENT sid="143" pm="."><plain>This finding is consistent with those of similarly designed studies in AS using the same comparator treatment.24,25 </plain></SENT>
</text></p><p><text><SENT sid="144" pm="."><plain>According to previous reports,24,25 celecoxib 400 mg once daily reduces some parameters of inflammation more effectively than celecoxib 200 mg once daily, suggesting a possible dose-dependent effect and potentially better treatment outcomes with the higher dose. </plain></SENT>
<SENT sid="145" pm="."><plain>The results of our analysis support this. </plain></SENT>
<SENT sid="146" pm="."><plain>At the end of the extension period (Week 12), celecoxib 400 mg once daily noticeably advanced the extent of improvements in patients who did not achieve satisfactory improvement in signs and symptoms after 6 weeks of treatment with celecoxib 200 mg once daily. </plain></SENT>
</text></p><p><text><SENT sid="147" pm="."><plain>GI disorders are a well-known side effect of NSAID use;29,30 however, celecoxib, a selective inhibitor of the inducible form of the COX enzyme (ie, COX-2), is thought to be better tolerated and associated with fewer AEs than the more traditional nsNSAIDs that act via nonselective inhibition of both COX-1 and COX-2.31–35 Notably, in the Celecoxib versus Omeprazole and Diclofenac for at-Risk Osteoarthritis and Rheumatoid Arthritis Patients trial, the rate of predefined and adjudicated clinically significant upper and lower GI events (the primary end point) was 4 times higher in patients with arthritis at increased GI risk who were receiving diclofenac SR 75 mg twice daily plus omeprazole 20 mg once daily than in those receiving celecoxib 200 mg twice daily during 6 months of treatment.36 </plain></SENT>
</text></p><p><text><SENT sid="148" pm="."><plain>In our study, although GI disorders were the most frequently reported treatment-related AEs in both treatment groups during the double-blind phase, a similar number of GI AEs and discontinuations due to GI AEs were reported in patients receiving celecoxib 200 mg once daily compared with diclofenac SR 75 mg once daily. </plain></SENT>
<SENT sid="149" pm="."><plain>Furthermore, patients receiving the higher celecoxib 400 mg once daily dose throughout the 6-week extension phase also reported a similar number of GI AEs and discontinuations compared with patients receiving diclofenac SR 75 mg once daily. </plain></SENT>
<SENT sid="150" pm="."><plain>Our results, which suggest that treatment with celecoxib is not only well tolerated but associated with a low frequency of GI AEs are also consistent with those of previous study outcomes in patients with AS24,25 and arthritis.29,30,36 </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusions" id="s0110"><title><text><SENT sid="151" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="152" pm="."><plain>Consistent with previous findings in AS, our results suggest that the efficacy of celecoxib 200 mg once daily is noninferior to diclofenac SR 75 mg once daily over 6 weeks of treatment in Chinese patients with AS. </plain></SENT>
<SENT sid="153" pm="."><plain>Furthermore, the use of celecoxib 400 mg once daily was not associated with any additional AEs or tolerability issues compared with diclofenac SR 75 mg once daily over a 6-week treatment extension. </plain></SENT>
</text></p></sec></SecTag><SecTag type="COMP_INT"><sec id="s0115"><title><text><SENT sid="154" pm="."><plain>Conflicts of Interest </plain></SENT>
</text></title><p><text><SENT sid="155" pm="."><plain>This study was sponsored by Pfizer Inc., who were responsible for the collection, analysis and interpretation of the data. </plain></SENT>
<SENT sid="156" pm="."><plain>Authors affiliated with Pfizer Inc. assisted with the writing and submission of the manuscript. </plain></SENT>
<SENT sid="157" pm="."><plain>Jin Fu and Sharon Pan are full-time employees of Pfizer Inc. </plain></SENT>
<SENT sid="158" pm="."><plain>Shi Le was a full-time employee of Pfizer Inc during the study and the manuscript development. </plain></SENT>
<SENT sid="159" pm="."><plain>The authors have indicated that they have no other conflicts of interest regarding the content of this article. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="REF"><ref-list><title>References</title><ref id="bib1"><text><SENT sid="160" pm="."><plain>1ArnettF.C.Seronegative spondylarthropathiesBull Rheum Dis3719871123326644 </plain></SENT>
</text></ref><ref id="bib2"><text><SENT sid="161" pm="."><plain>2DougadosM.BehierJ.M.JolchineI.Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drugArthritis Rheum44200118018511212158 </plain></SENT>
</text></ref><ref id="bib3"><text><SENT sid="162" pm="."><plain>3ChenH.H.ChenT.J.ChenY.M.Ying-MingC.ChenD.Y.Gender differences in ankylosing spondylitis-associated cumulative healthcare utilization: a population-based cohort studyClinics (Sao Paulo)66201125125421484042 </plain></SENT>
</text></ref><ref id="bib4"><text><SENT sid="163" pm="."><plain>4ZinkA.BraunJ.ListingJ.WollenhauptJ.Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. </plain></SENT>
<SENT sid="164" pm="."><plain>German Collaborative Arthritis CentersJ Rheumatol27200061362210743798 </plain></SENT>
</text></ref><ref id="bib5"><text><SENT sid="165" pm="."><plain>5van der LindenS.ValkenburgH.A.CatsA.Evaluation of diagnostic criteria for ankylosing spondylitis. </plain></SENT>
<SENT sid="166" pm="."><plain>A proposal for modification of the New York criteriaArthritis Rheum2719843613686231933 </plain></SENT>
</text></ref><ref id="bib6"><text><SENT sid="167" pm="."><plain>6WandersA.HeijdeD.LandewéR.Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trialArthritis Rheum5220051756176515934081 </plain></SENT>
</text></ref><ref id="bib7"><text><SENT sid="168" pm="."><plain>7Chinese Association of RheumatologyDiagnosis and treatment guideline for Ankylosing SpondylitisChin J Rheumatol142010557559 </plain></SENT>
</text></ref><ref id="bib8"><text><SENT sid="169" pm="."><plain>8Garcia RodriguezL.A.JickH.Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugsLancet34319947697727907735 </plain></SENT>
</text></ref><ref id="bib9"><text><SENT sid="170" pm="."><plain>9KhannaD.McMahonM.FurstD.E.Safety of tumour necrosis factor-alpha antagonistsDrug Saf27200430732415061685 </plain></SENT>
</text></ref><ref id="bib10"><text><SENT sid="171" pm="?"><plain>10KearneyP.M.BaigentC.GodwinJ.HallsH.EmbersonJ.R.PatronoC.Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? </plain></SENT>
<SENT sid="172" pm="."><plain>Meta-analysis of randomised trialsBMJ33220061302130816740558 </plain></SENT>
</text></ref><ref id="bib11"><text><SENT sid="173" pm="."><plain>11McGettiganP.HenryD.Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2JAMA29620061633164416968831 </plain></SENT>
</text></ref><ref id="bib12"><text><SENT sid="174" pm="."><plain>12McGettiganP.HenryD.Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studiesPLoS Med82011e100109821980265 </plain></SENT>
</text></ref><ref id="bib13"><text><SENT sid="175" pm="."><plain>13SolomonD.H.GlynnR.J.RothmanK.J.Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groupsArthritis Rheum5920081097110418668605 </plain></SENT>
</text></ref><ref id="bib14"><text><SENT sid="176" pm="."><plain>14BonnerG.F.WalczakM.KitchenL.BayonaM.Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel diseaseAm J Gastroenterol9520001946194810950040 </plain></SENT>
</text></ref><ref id="bib15"><text><SENT sid="177" pm="."><plain>15De KeyserF.ElewautD.DeV.M.Bowel inflammation and the spondyloarthropathiesRheum Dis Clin North Am241998785813(ix-x)9891711 </plain></SENT>
</text></ref><ref id="bib16"><text><SENT sid="178" pm="."><plain>16EvansJ.M.McMahonA.D.MurrayF.E.McDevittD.G.MacDonaldT.M.Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel diseaseGut4019976196229203940 </plain></SENT>
</text></ref><ref id="bib17"><text><SENT sid="179" pm="."><plain>17FelderJ.B.KorelitzB.I.RajapakseR.SchwarzS.HoratagisA.P.GleimG.Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control studyAm J Gastroenterol9520001949195410950041 </plain></SENT>
</text></ref><ref id="bib18"><text><SENT sid="180" pm="."><plain>18GibsonG.R.WhitacreE.B.RicottiC.A.Colitis induced by nonsteroidal anti-inflammatory drugs. </plain></SENT>
<SENT sid="181" pm="."><plain>Report of four cases and review of the literatureArch Intern Med15219926256321546927 </plain></SENT>
</text></ref><ref id="bib19"><text><SENT sid="182" pm="."><plain>19BrandtJ.HaibelH.CornelyD.Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximabArthritis Rheum4320001346135210857793 </plain></SENT>
</text></ref><ref id="bib20"><text><SENT sid="183" pm="."><plain>20GormanJ.D.SackK.E.DavisJ.Jr.Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alphaN Engl J Med34620021349135611986408 </plain></SENT>
</text></ref><ref id="bib21"><text><SENT sid="184" pm="."><plain>21DeeksJ.J.SmithL.A.BradleyM.D.Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trialsBMJ325200261912242171 </plain></SENT>
</text></ref><ref id="bib22"><text><SENT sid="185" pm="."><plain>22DougadosM.DijkmansB.KhanM.MaksymowychW.van der LindenS.BrandtJ.Conventional treatments for ankylosing spondylitisAnn Rheum Dis61Suppl 32002iii40iii5012381510 </plain></SENT>
</text></ref><ref id="bib23"><text><SENT sid="186" pm="."><plain>23WhiteW.B.WestC.R.BorerJ.S.Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trialsAm J Cardiol992007919817196469 </plain></SENT>
</text></ref><ref id="bib24"><text><SENT sid="187" pm="."><plain>24BarkhuizenA.SteinfeldS.RobbinsJ.WestC.CoombsJ.ZwillichS.Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitisJ Rheumatol3320061805181216960941 </plain></SENT>
</text></ref><ref id="bib25"><text><SENT sid="188" pm="."><plain>25SieperJ.KlopschT.RichterM.Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled studyAnn Rheum Dis67200832332917616556 </plain></SENT>
</text></ref><ref id="bib26"><text><SENT sid="189" pm="."><plain>26ZochlingJ.Bohl-BuhlerM.H.BaraliakosX.FeldtkellerE.BraunJ.Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based surveyClin Rheumatol25200679480016528455 </plain></SENT>
</text></ref><ref id="bib27"><text><SENT sid="190" pm="."><plain>27LaineL.CurtisS.P.CryerB.KaurA.CannonC.P.Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonLancet369200746547317292766 </plain></SENT>
</text></ref><ref id="bib28"><text><SENT sid="191" pm="."><plain>28KellnerH.L.LiC.EssexM.N.Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trialCurr Med Res Opin2820121537154522852870 </plain></SENT>
</text></ref><ref id="bib29"><text><SENT sid="192" pm="."><plain>29AllisonM.C.HowatsonA.G.TorranceC.J.LeeF.D.RussellR.I.Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugsN Engl J Med32719927497541501650 </plain></SENT>
</text></ref><ref id="bib30"><text><SENT sid="193" pm="."><plain>30LanasA.SopenaF.Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complicationsGastroenterol Clin North Am38200933335219446262 </plain></SENT>
</text></ref><ref id="bib31"><text><SENT sid="194" pm="."><plain>31BensenW.G.ZhaoS.Z.BurkeT.A.Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placeboJ Rheumatol2720001876188310955327 </plain></SENT>
</text></ref><ref id="bib32"><text><SENT sid="195" pm="."><plain>32GoldsteinJ.L.SilversteinF.E.AgrawalN.M.Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitorAm J Gastroenterol9520001681169010925968 </plain></SENT>
</text></ref><ref id="bib33"><text><SENT sid="196" pm="."><plain>33McKennaF.ArguellesL.BurkeT.LefkowithJ.GeisG.S.Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritisClin Exp Rheumatol202002354311892706 </plain></SENT>
</text></ref><ref id="bib34"><text><SENT sid="197" pm="."><plain>34SilversteinF.E.FaichG.GoldsteinJ.L.Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. </plain></SENT>
<SENT sid="198" pm="."><plain>Celecoxib Long-term Arthritis Safety StudyJAMA28420001247125510979111 </plain></SENT>
</text></ref><ref id="bib35"><text><SENT sid="199" pm="."><plain>35SinghG.FortJ.G.GoldsteinJ.L.Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I StudyAm J Med119200625526616490472 </plain></SENT>
</text></ref><ref id="bib36"><text><SENT sid="200" pm="."><plain>36ChanF.K.LanasA.ScheimanJ.BergerM.F.NguyenH.GoldsteinJ.L.Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trialLancet376201017317920638563 </plain></SENT>
</text></ref></ref-list></SecTag><SecTag type="ACK_FUND"><ack id="ack0005"><title>Acknowledgments</title><p><text4fund><text><SENT sid="201" pm="."><plain>The authors thank Zhuang Liu and Qing Gu for their advice and assistance in the preparation of the manuscript. </plain></SENT>
<SENT sid="202" pm="."><plain>Editorial support was provided by K. </plain></SENT>
<SENT sid="203" pm="."><plain>Bradford, PhD; Christina Campbell, PhD; and L. </plain></SENT>
<SENT sid="204" pm="."><plain>Prevost of PAREXEL, and was funded by Pfizer Inc. </plain></SENT>
<SENT sid="205" pm="."><plain>We confirm that all authors contributed to the writing, reviewing, preparation, and interpretation of the data, and gave final approval of the manuscript for submission. </plain></SENT>
</text></text4fund></p></ack></SecTag></back><floats-group><SecTag type="FIG"><fig id="f0005"><label>Figure 1</label><caption><p><text><SENT sid="206" pm="."><plain>Study design. </plain></SENT>
<SENT sid="207" pm="."><plain>NSAID = nonsteroidal anti-inflammatory drug; SR = sustained release. </plain></SENT>
</text></p></caption><graphic xlink:href="gr1"/></fig></SecTag><SecTag type="FIG"><fig id="f0010"><label>Figure 2</label><caption><p><text><SENT sid="208" pm="."><plain>Flow of patients through the study. </plain></SENT>
<SENT sid="209" pm="."><plain>SR = sustained release. </plain></SENT>
</text></p></caption><graphic xlink:href="gr2"/></fig></SecTag><SecTag type="FIG"><fig id="f0015"><label>Figure 3</label><caption><p><text><SENT sid="210" pm="."><plain>Changes from baseline in Patient’s Global Assessment of Pain Intensity score (per-protocol analysis set) at Week 6. </plain></SENT>
<SENT sid="211" pm="."><plain>LS = least squares; SR = sustained release. </plain></SENT>
</text></p></caption><graphic xlink:href="gr3"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="t0005" position="float"><label>Table I</label><caption><p><text><SENT sid="212" pm="."><plain>Baseline patient demographics and disease characteristics (full analysis set). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><text><SENT sid="213" pm="."><plain>Patient demographic </plain></SENT>
</text></th><th colspan="2" align="center"><text><SENT sid="214" pm="."><plain>Celecoxib 200 mg once daily (n = 120) </plain></SENT>
</text></th><th colspan="2" align="center"><text><SENT sid="215" pm="."><plain>Diclofenac SR 75 mg once daily (n = 120) </plain></SENT>
</text></th><th rowspan="2" align="center"><text><SENT sid="216" pm="."><plain>Total (N = 240) </plain></SENT>
</text></th></tr><tr><th align="center"><text><SENT sid="217" pm="."><plain>Men (n = 105) </plain></SENT>
</text></th><th align="center"><text><SENT sid="218" pm="."><plain>Women (n = 15) </plain></SENT>
</text></th><th align="center"><text><SENT sid="219" pm="."><plain>Men (n = 101) </plain></SENT>
</text></th><th align="center"><text><SENT sid="220" pm="."><plain>Women (n = 19) </plain></SENT>
</text></th></tr></thead><tbody><tr><td><text><SENT sid="221" pm="."><plain>Age, y </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="222" pm="."><plain> 18–44* </plain></SENT>
</text></td><td align="center"><text><SENT sid="223" pm="."><plain>97 (92.4) </plain></SENT>
</text></td><td align="center"><text><SENT sid="224" pm="."><plain>12 (80.0) </plain></SENT>
</text></td><td align="center"><text><SENT sid="225" pm="."><plain>91 (90.1) </plain></SENT>
</text></td><td align="center"><text><SENT sid="226" pm="."><plain>18 (94.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="227" pm="."><plain>218 (90.8) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="228" pm="."><plain> 45–64* </plain></SENT>
</text></td><td align="center"><text><SENT sid="229" pm="."><plain>8 (7.6) </plain></SENT>
</text></td><td align="center"><text><SENT sid="230" pm="."><plain>3 (20.0) </plain></SENT>
</text></td><td align="center"><text><SENT sid="231" pm="."><plain>10 (9.9) </plain></SENT>
</text></td><td align="center"><text><SENT sid="232" pm="."><plain>1 (5.3) </plain></SENT>
</text></td><td align="center"><text><SENT sid="233" pm="."><plain>22 (9.2) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="234" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="235" pm="."><plain>29.5 (8.9) </plain></SENT>
</text></td><td align="center"><text><SENT sid="236" pm="."><plain>31.6 (10.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="237" pm="."><plain>28.8 (9.1) </plain></SENT>
</text></td><td align="center"><text><SENT sid="238" pm="."><plain>29.5 (7.2) </plain></SENT>
</text></td><td align="center"><text><SENT sid="239" pm="."><plain>29.3 (9.0) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="240" pm="."><plain> Range </plain></SENT>
</text></td><td align="center"><text><SENT sid="241" pm="."><plain>18–58 </plain></SENT>
</text></td><td align="center"><text><SENT sid="242" pm="."><plain>19–53 </plain></SENT>
</text></td><td align="center"><text><SENT sid="243" pm="."><plain>18–59 </plain></SENT>
</text></td><td align="center"><text><SENT sid="244" pm="."><plain>20–45 </plain></SENT>
</text></td><td align="center"><text><SENT sid="245" pm="."><plain>18–59 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="246" pm="."><plain>Weight, kg </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="247" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="248" pm="."><plain>66.5 (11.8) </plain></SENT>
</text></td><td align="center"><text><SENT sid="249" pm="."><plain>52.1 (7.3) </plain></SENT>
</text></td><td align="center"><text><SENT sid="250" pm="."><plain>66.3 (11.8) </plain></SENT>
</text></td><td align="center"><text><SENT sid="251" pm="."><plain>53.4 (9.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="252" pm="."><plain>64.5 (12.3) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="253" pm="."><plain> Range </plain></SENT>
</text></td><td align="center"><text><SENT sid="254" pm="."><plain>47.0–108.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="255" pm="."><plain>35.0–62.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="256" pm="."><plain>46.0–93.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="257" pm="."><plain>42.0–75.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="258" pm="."><plain>35.0–108.0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="259" pm="."><plain>Body mass index </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="260" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="261" pm="."><plain>22.7 (3.6) </plain></SENT>
</text></td><td align="center"><text><SENT sid="262" pm="."><plain>20.1 (2.3) </plain></SENT>
</text></td><td align="center"><text><SENT sid="263" pm="."><plain>22.4 (3.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="264" pm="."><plain>21.0 (3.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="265" pm="."><plain>22.3 (3.6) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="266" pm="."><plain> Range </plain></SENT>
</text></td><td align="center"><text><SENT sid="267" pm="."><plain>17.2–34.5 </plain></SENT>
</text></td><td align="center"><text><SENT sid="268" pm="."><plain>15.6–23.4 </plain></SENT>
</text></td><td align="center"><text><SENT sid="269" pm="."><plain>16.0–31.5 </plain></SENT>
</text></td><td align="center"><text><SENT sid="270" pm="."><plain>16.2–27.9 </plain></SENT>
</text></td><td align="center"><text><SENT sid="271" pm="."><plain>15.6–34.5 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="272" pm="."><plain>Height, cm </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="273" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="274" pm="."><plain>170.9 (5.4) </plain></SENT>
</text></td><td align="center"><text><SENT sid="275" pm="."><plain>160.9 (5.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="276" pm="."><plain>171.9 (5.9) </plain></SENT>
</text></td><td align="center"><text><SENT sid="277" pm="."><plain>159.4 (4.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="278" pm="."><plain>169.8 (6.8) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="279" pm="."><plain> Range </plain></SENT>
</text></td><td align="center"><text><SENT sid="280" pm="."><plain>158.0–185.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="281" pm="."><plain>150.0–175.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="282" pm="."><plain>150.0–184.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="283" pm="."><plain>150.0–170.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="284" pm="."><plain>150.0–185.0 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>SR = sustained release.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblIfnStar"><label>⁎</label><p>Values are given as n (%) unless otherwise noted.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t0010" position="float"><label>Table II</label><caption><p><text><SENT sid="285" pm="."><plain>Patient’s Global Assessment of Pain Intensity score at baseline to Week 2, 4, and 6 in the double-blind period (full analysis set). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th><text><SENT sid="286" pm="."><plain>Characteristic </plain></SENT>
</text></th><th align="center"><text><SENT sid="287" pm="."><plain>Celecoxib 200 mg once daily (n = 120) </plain></SENT>
</text></th><th align="center"><text><SENT sid="288" pm="."><plain>Diclofenac SR 75 mg once daily (n = 120) </plain></SENT>
</text></th><th align="center"><text><SENT sid="289" pm="."><plain>Difference (celecoxib 200 mg once daily – diclofenac SR 75 mg once daily) </plain></SENT>
</text></th></tr></thead><tbody><tr><td><text><SENT sid="290" pm="."><plain>Baseline </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="291" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="292" pm="."><plain>117 </plain></SENT>
</text></td><td align="center"><text><SENT sid="293" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="294" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="295" pm="."><plain>63.1 (12.84) </plain></SENT>
</text></td><td align="center"><text><SENT sid="296" pm="."><plain>63.7 (13.28) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="297" pm="."><plain>Change from baseline to Week 2 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="298" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="299" pm="."><plain>116 </plain></SENT>
</text></td><td align="center"><text><SENT sid="300" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="301" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="302" pm="."><plain>–18.4 (19.39) </plain></SENT>
</text></td><td align="center"><text><SENT sid="303" pm="."><plain>–17.7 (19.69) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="304" pm="."><plain> LS mean (SE)* </plain></SENT>
</text></td><td align="center"><text><SENT sid="305" pm="."><plain>–18.6 (1.78) </plain></SENT>
</text></td><td align="center"><text><SENT sid="306" pm="."><plain>–17.9 (1.79) </plain></SENT>
</text></td><td align="center"><text><SENT sid="307" pm="."><plain>–0.7 (2.5) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="308" pm="."><plain> 95% CI† </plain></SENT>
</text></td><td align="center"><text><SENT sid="309" pm="."><plain>–22.1 to –15.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="310" pm="."><plain>–21.4 to –14.3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="311" pm="."><plain>–5.6 to 4.2 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="312" pm="."><plain> P value* </plain></SENT>
</text></td><td align="center"><text><SENT sid="313" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="314" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="315" pm="."><plain>0.7849 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="316" pm="."><plain>Change from baseline to Week 4 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="317" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="318" pm="."><plain>117 </plain></SENT>
</text></td><td align="center"><text><SENT sid="319" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="320" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="321" pm="."><plain>–20.7 (20.52) </plain></SENT>
</text></td><td align="center"><text><SENT sid="322" pm="."><plain>–23.4 (21.61) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="323" pm="."><plain> LS mean (SE) </plain></SENT>
</text></td><td align="center"><text><SENT sid="324" pm="."><plain>–20.7 (1.86) </plain></SENT>
</text></td><td align="center"><text><SENT sid="325" pm="."><plain>–23.3 (1.89) </plain></SENT>
</text></td><td align="center"><text><SENT sid="326" pm="."><plain>2.6 (2.62) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="327" pm="."><plain> 95% CI </plain></SENT>
</text></td><td align="center"><text><SENT sid="328" pm="."><plain>–24.4 to –17.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="329" pm="."><plain>–27.1 to –19.6 </plain></SENT>
</text></td><td align="center"><text><SENT sid="330" pm="."><plain>–2.6 to 7.8 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="331" pm="."><plain> P value </plain></SENT>
</text></td><td align="center"><text><SENT sid="332" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="333" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="334" pm="."><plain>0.3223 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="335" pm="."><plain>Change from baseline to Week 6 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="336" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="337" pm="."><plain>117 </plain></SENT>
</text></td><td align="center"><text><SENT sid="338" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="339" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="340" pm="."><plain>–23.7 (20.61) </plain></SENT>
</text></td><td align="center"><text><SENT sid="341" pm="."><plain>–26.7 (22.85) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="342" pm="."><plain> LS mean (SE) </plain></SENT>
</text></td><td align="center"><text><SENT sid="343" pm="."><plain>–23.8 (1.92) </plain></SENT>
</text></td><td align="center"><text><SENT sid="344" pm="."><plain>–26.8 (1.95) </plain></SENT>
</text></td><td align="center"><text><SENT sid="345" pm="."><plain>3.1 (2.71) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="346" pm="."><plain> 95% CI </plain></SENT>
</text></td><td align="center"><text><SENT sid="347" pm="."><plain>–27.5 to –20.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="348" pm="."><plain>–30.7 to –23.0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="349" pm="."><plain>–2.3 to 8.4 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="350" pm="."><plain> P value </plain></SENT>
</text></td><td align="center"><text><SENT sid="351" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="352" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="353" pm="."><plain>0.2598 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>LS = least squares; SR = sustained release.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblIIfnStar"><label>⁎</label><p>Estimated from analysis of covariance model with treatment and center as factors and baseline as covariate.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblIIfnDagger"><label>†</label><p>Noninferiority considered if the upper bound of the CI &lt;10.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t0015" position="float"><label>Table III</label><caption><p><text><SENT sid="354" pm="."><plain>Patient’s Global Assessment of Disease Activity score at baseline to Week 2, 4, and 6 in the double-blind period (full analysis set). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th><text><SENT sid="355" pm="."><plain>Characteristic </plain></SENT>
</text></th><th align="center"><text><SENT sid="356" pm="."><plain>Celecoxib 200 mg once daily (n = 120) </plain></SENT>
</text></th><th align="center"><text><SENT sid="357" pm="."><plain>Diclofenac SR 75 mg once daily (n = 120) </plain></SENT>
</text></th><th align="center"><text><SENT sid="358" pm="."><plain>Difference (celecoxib 200 mg once daily – diclofenac SR 75 mg once daily) </plain></SENT>
</text></th></tr></thead><tbody><tr><td><text><SENT sid="359" pm="."><plain>Baseline </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="360" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="361" pm="."><plain>117 </plain></SENT>
</text></td><td align="center"><text><SENT sid="362" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="363" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="364" pm="."><plain>3.2 (0.73) </plain></SENT>
</text></td><td align="center"><text><SENT sid="365" pm="."><plain>3.1 (0.67) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="366" pm="."><plain>Change from baseline to Week 2 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="367" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="368" pm="."><plain>116 </plain></SENT>
</text></td><td align="center"><text><SENT sid="369" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="370" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="371" pm="."><plain>–0.4 (0.72) </plain></SENT>
</text></td><td align="center"><text><SENT sid="372" pm="."><plain>–0.4 (0.72) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="373" pm="."><plain> LS mean (SE)* </plain></SENT>
</text></td><td align="center"><text><SENT sid="374" pm="."><plain>–0.4 (0.06) </plain></SENT>
</text></td><td align="center"><text><SENT sid="375" pm="."><plain>–0.4 (0.06) </plain></SENT>
</text></td><td align="center"><text><SENT sid="376" pm="."><plain>0.0 (0.08) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="377" pm="."><plain> 95% CI† </plain></SENT>
</text></td><td align="center"><text><SENT sid="378" pm="."><plain>–0.5 to –0.3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="379" pm="."><plain>–0.5 to –0.3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="380" pm="."><plain>–0.15 to 0.17 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="381" pm="."><plain> P value* </plain></SENT>
</text></td><td align="center"><text><SENT sid="382" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="383" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="384" pm="."><plain>0.8938 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="385" pm="."><plain>Change from baseline to Week 4 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="386" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="387" pm="."><plain>117 </plain></SENT>
</text></td><td align="center"><text><SENT sid="388" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="389" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="390" pm="."><plain>–0.3 (0.74) </plain></SENT>
</text></td><td align="center"><text><SENT sid="391" pm="."><plain>–0.4 (0.67) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="392" pm="."><plain> LS mean (SE) </plain></SENT>
</text></td><td align="center"><text><SENT sid="393" pm="."><plain>–0.3 (0.06) </plain></SENT>
</text></td><td align="center"><text><SENT sid="394" pm="."><plain>–0.4 (0.06) </plain></SENT>
</text></td><td align="center"><text><SENT sid="395" pm="."><plain>0.2 (0.08) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="396" pm="."><plain> 95% CI </plain></SENT>
</text></td><td align="center"><text><SENT sid="397" pm="."><plain>–0.4 to –0.2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="398" pm="."><plain>–0.5 to –0.3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="399" pm="."><plain>0.01 to 0.31 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="400" pm="."><plain> P value </plain></SENT>
</text></td><td align="center"><text><SENT sid="401" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="402" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="403" pm="."><plain>0.0426 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="404" pm="."><plain>Change from baseline to Week 6 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="405" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="406" pm="."><plain>117 </plain></SENT>
</text></td><td align="center"><text><SENT sid="407" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="408" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="409" pm="."><plain>–0.3 (0.76) </plain></SENT>
</text></td><td align="center"><text><SENT sid="410" pm="."><plain>–0.4 (0.74) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="411" pm="."><plain> LS Mean (SE) </plain></SENT>
</text></td><td align="center"><text><SENT sid="412" pm="."><plain>–0.3 (0.06) </plain></SENT>
</text></td><td align="center"><text><SENT sid="413" pm="."><plain>–0.4 (0.06) </plain></SENT>
</text></td><td align="center"><text><SENT sid="414" pm="."><plain>0.1 (0.09) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="415" pm="."><plain> 95% CI </plain></SENT>
</text></td><td align="center"><text><SENT sid="416" pm="."><plain>–0.4 to –0.2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="417" pm="."><plain>–0.5 to –0.3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="418" pm="."><plain>–0.05 to 0.29 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="419" pm="."><plain> P value </plain></SENT>
</text></td><td align="center"><text><SENT sid="420" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="421" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="422" pm="."><plain>0.1502 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>LS = least squares; SR = sustained release.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblIIIfnStar"><label>⁎</label><p>Estimated from analysis of covariance model with treatment and center as factors and baseline as covariate.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblIIIfnDagger"><label>†</label><p>Noninferiority considered if the upper bound of the CI &lt;10.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t0020" position="float"><label>Table IV</label><caption><p><text><SENT sid="423" pm="."><plain>Physician’s Global Assessment of Disease Activity score at baseline to Week 2, 4, and 6 in the double-blind period (full analysis set). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th><text><SENT sid="424" pm="."><plain>Characteristic </plain></SENT>
</text></th><th align="center"><text><SENT sid="425" pm="."><plain>Celecoxib 200 mg once daily (n = 120) </plain></SENT>
</text></th><th align="center"><text><SENT sid="426" pm="."><plain>Diclofenac SR 75 mg once daily (n = 120) </plain></SENT>
</text></th><th align="center"><text><SENT sid="427" pm="."><plain>Difference (celecoxib 200 mg once daily – diclofenac SR 75 mg once daily) </plain></SENT>
</text></th></tr></thead><tbody><tr><td><text><SENT sid="428" pm="."><plain>Baseline </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="429" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="430" pm="."><plain>117 </plain></SENT>
</text></td><td align="center"><text><SENT sid="431" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="432" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="433" pm="."><plain>3.2 (0.51) </plain></SENT>
</text></td><td align="center"><text><SENT sid="434" pm="."><plain>3.2 (0.52) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="435" pm="."><plain>Change from baseline to Week 2 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="436" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="437" pm="."><plain>116 </plain></SENT>
</text></td><td align="center"><text><SENT sid="438" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="439" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="440" pm="."><plain>–0.4 (0.65) </plain></SENT>
</text></td><td align="center"><text><SENT sid="441" pm="."><plain>–0.3 (0.56) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="442" pm="."><plain> LS mean (SE)* </plain></SENT>
</text></td><td align="center"><text><SENT sid="443" pm="."><plain>–0.4 (0.05) </plain></SENT>
</text></td><td align="center"><text><SENT sid="444" pm="."><plain>–0.4 (0.05) </plain></SENT>
</text></td><td align="center"><text><SENT sid="445" pm="."><plain>0.0 (0.07) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="446" pm="."><plain> 95% CI† </plain></SENT>
</text></td><td align="center"><text><SENT sid="447" pm="."><plain>–0.5 to –0.3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="448" pm="."><plain>–0.5 to –0.3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="449" pm="."><plain>–0.2 to 0.1 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="450" pm="."><plain> P value* </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"><text><SENT sid="451" pm="."><plain>0.5945 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="452" pm="."><plain>Change from baseline to Week 4 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="453" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="454" pm="."><plain>117 </plain></SENT>
</text></td><td align="center"><text><SENT sid="455" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="456" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="457" pm="."><plain>–0.4 (0.62) </plain></SENT>
</text></td><td align="center"><text><SENT sid="458" pm="."><plain>–0.5 (0.64) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="459" pm="."><plain> LS mean (SE) </plain></SENT>
</text></td><td align="center"><text><SENT sid="460" pm="."><plain>–0.4 (0.05) </plain></SENT>
</text></td><td align="center"><text><SENT sid="461" pm="."><plain>–0.5 (0.05) </plain></SENT>
</text></td><td align="center"><text><SENT sid="462" pm="."><plain>0.1 (0.07) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="463" pm="."><plain> 95% CI </plain></SENT>
</text></td><td align="center"><text><SENT sid="464" pm="."><plain>–0.5 to –0.3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="465" pm="."><plain>–0.6 to –0.4 </plain></SENT>
</text></td><td align="center"><text><SENT sid="466" pm="."><plain>–0.1 to 0.2 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="467" pm="."><plain> P value </plain></SENT>
</text></td><td align="center"><text><SENT sid="468" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="469" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="470" pm="."><plain>0.3427 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="471" pm="."><plain>Change from baseline to Week 6 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="472" pm="."><plain> N </plain></SENT>
</text></td><td align="center"><text><SENT sid="473" pm="."><plain>117 </plain></SENT>
</text></td><td align="center"><text><SENT sid="474" pm="."><plain>115 </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="475" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td align="center"><text><SENT sid="476" pm="."><plain>–0.5 (0.68) </plain></SENT>
</text></td><td align="center"><text><SENT sid="477" pm="."><plain>–0.5 (0.70) </plain></SENT>
</text></td><td align="center"/></tr><tr><td><text><SENT sid="478" pm="."><plain> LS mean (SE) </plain></SENT>
</text></td><td align="center"><text><SENT sid="479" pm="."><plain>–0.5 (0.06) </plain></SENT>
</text></td><td align="center"><text><SENT sid="480" pm="."><plain>–0.5 (0.06) </plain></SENT>
</text></td><td align="center"><text><SENT sid="481" pm="."><plain>0.0 (0.08) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="482" pm="."><plain> 95% CI </plain></SENT>
</text></td><td align="center"><text><SENT sid="483" pm="."><plain>–0.6 to –0.4 </plain></SENT>
</text></td><td align="center"><text><SENT sid="484" pm="."><plain>–0.6 to –0.4 </plain></SENT>
</text></td><td align="center"><text><SENT sid="485" pm="."><plain>–0.1 to 0.2 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="486" pm="."><plain> P value </plain></SENT>
</text></td><td align="center"><text><SENT sid="487" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="488" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="489" pm="."><plain>0.6522 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>LS = least squares; SR = sustained release.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblIVfnStar"><label>⁎</label><p>Estimated from analysis of covariance model with treatment and center as factors and baseline as covariate.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblIVfnDagger"><label>†</label><p>Noninferiority considered if the upper bound of the CI &lt;10.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t0025" position="float"><label>Table V</label><caption><p><text><SENT sid="490" pm="."><plain>Analyses of Assessment in Ankylosing Spondylitis responders at Week 6 and Week 12 (extension phase). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th><text><SENT sid="491" pm="."><plain>C200 </plain></SENT>
</text></th><th><text><SENT sid="492" pm="."><plain>D75 </plain></SENT>
</text></th><th><text><SENT sid="493" pm="."><plain>C200/C400 </plain></SENT>
</text></th><th><text><SENT sid="494" pm="."><plain>D75/C400 </plain></SENT>
</text></th></tr></thead><tbody><tr><td><text><SENT sid="495" pm="."><plain>Week 6 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="496" pm="."><plain> Total* </plain></SENT>
</text></td><td align="center"><text><SENT sid="497" pm="."><plain>54 </plain></SENT>
</text></td><td align="center"><text><SENT sid="498" pm="."><plain>54 </plain></SENT>
</text></td><td align="center"><text><SENT sid="499" pm="."><plain>54 </plain></SENT>
</text></td><td align="center"><text><SENT sid="500" pm="."><plain>54 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="501" pm="."><plain> Responders† </plain></SENT>
</text></td><td align="center"><text><SENT sid="502" pm="."><plain>22 (40.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="503" pm="."><plain>23 (42.6) </plain></SENT>
</text></td><td align="center"><text><SENT sid="504" pm="."><plain>12 (22.2) </plain></SENT>
</text></td><td align="center"><text><SENT sid="505" pm="."><plain>16 (29.6) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="506" pm="."><plain>Week 12 </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="507" pm="."><plain> Total* </plain></SENT>
</text></td><td align="center"><text><SENT sid="508" pm="."><plain>51 </plain></SENT>
</text></td><td align="center"><text><SENT sid="509" pm="."><plain>53 </plain></SENT>
</text></td><td align="center"><text><SENT sid="510" pm="."><plain>46 </plain></SENT>
</text></td><td align="center"><text><SENT sid="511" pm="."><plain>51 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="512" pm="."><plain> Responders† </plain></SENT>
</text></td><td align="center"><text><SENT sid="513" pm="."><plain>25 (49.0) </plain></SENT>
</text></td><td align="center"><text><SENT sid="514" pm="."><plain>25 (47.2) </plain></SENT>
</text></td><td align="center"><text><SENT sid="515" pm="."><plain>15 (32.6) </plain></SENT>
</text></td><td align="center"><text><SENT sid="516" pm="."><plain>19 (37.3) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>C200 = celecoxib 200 mg once daily during double-blind and extension phase; D75 = diclofenac sustained release 75 mg once daily during double-blind and extension phase; C200/C400 = celecoxib 200 mg once daily during double-blind phase and celecoxib 400 mg once daily during extension phase; D75/C400 = diclofenac sustained release 75 mg once daily during double-blind phase and celecoxib 400 mg once daily during extension phase.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblVfnStar"><label>⁎</label><p>Total number of patients with data at baseline and week.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblVfnDagger"><label>†</label><p>Those patients showing improvement of at least 20% from baseline and absolute improvement of at least 10 mm on a 0 to 100 scale in at least 3 of the following 4 domains: Patient’s Global Assessment of Disease Activity, Patient’s Assessment of Global Pain Intensity, Functional impairment according to Bath Ankylosing Spondylitis Functional Index, Inflammation (defined as mean value for Bath Ankylosing Spondylitis Disease Activity Index morning stiffness intensity and morning stiffness duration). In any domain for which a patient did not demonstrate improvement, the patient must not have shown deterioration, with deterioration defined as a reduction that was both ≥20% and ≥10 mm. Values are presented as n (%).</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t0030" position="float"><label>Table VI</label><caption><p><text><SENT sid="517" pm="."><plain>The incidence of treatment-emergent adverse events (AEs) (all causality and treatment-related) during the double-blind and extension phase.* </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="4" align="center"><text><SENT sid="518" pm="."><plain>All causality </plain></SENT>
</text></th><th colspan="4" align="center"><text><SENT sid="519" pm="."><plain>Treatment-related </plain></SENT>
</text></th></tr><tr><th colspan="2" align="center"><text><SENT sid="520" pm="."><plain>Celecoxib 200 mg once daily (n = 120) </plain></SENT>
</text></th><th colspan="2" align="center"><text><SENT sid="521" pm="."><plain>Diclofenac SR 75 mg once daily (n = 120) </plain></SENT>
</text></th><th colspan="2" align="center"><text><SENT sid="522" pm="."><plain>Celecoxib 200 mg once daily (n = 120) </plain></SENT>
</text></th><th colspan="2" align="center"><text><SENT sid="523" pm="."><plain>Diclofenac SR 75 mg once daily (n = 120) </plain></SENT>
</text></th></tr></thead><tbody><tr><td><text><SENT sid="524" pm="."><plain>Double-blind phase </plain></SENT>
</text></td><td colspan="2" align="center"/><td colspan="2" align="center"/><td colspan="2" align="center"/><td colspan="2" align="center"/></tr><tr><td><text><SENT sid="525" pm="."><plain>Number of patients </plain></SENT>
</text></td><td colspan="2" align="center"/><td colspan="2" align="center"/><td colspan="2" align="center"/><td colspan="2" align="center"/></tr><tr><td><text><SENT sid="526" pm="."><plain> With AEs </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="527" pm="."><plain>11 (9.2) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="528" pm="."><plain>9 (7.5) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="529" pm="."><plain>5 (4.2) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="530" pm="."><plain>8 (6.7) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="531" pm="."><plain> Discontinued due to AEs </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="532" pm="."><plain>2 (1.7) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="533" pm="."><plain>4 (3.3) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="534" pm="."><plain>2 (1.7) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="535" pm="."><plain>3 (2.5) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="536" pm="."><plain>Number of patients with AEs by system organ class </plain></SENT>
</text></td><td colspan="2" align="center"/><td colspan="2" align="center"/><td colspan="2" align="center"/><td colspan="2" align="center"/></tr><tr><td><text><SENT sid="537" pm="."><plain> Blood and lymphatic system disorders </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="538" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="539" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="540" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="541" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="542" pm="."><plain> Cardiac disorders </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="543" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="544" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="545" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="546" pm="."><plain>1 (0.8) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="547" pm="."><plain> Eye disorder </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="548" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="549" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="550" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="551" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="552" pm="."><plain> Gastrointestinal disorders </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="553" pm="."><plain>3 (2.5) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="554" pm="."><plain>4 (3.3) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="555" pm="."><plain>2 (1.7) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="556" pm="."><plain>4 (3.3) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="557" pm="."><plain> Hepatobiliary disorders </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="558" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="559" pm="."><plain>2 (1.7) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="560" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="561" pm="."><plain>2 (1.7) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="562" pm="."><plain> Infections and infestations </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="563" pm="."><plain>4 (3.3) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="564" pm="."><plain>2 (1.7) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="565" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="566" pm="."><plain>1 (0.8) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="567" pm="."><plain> Musculoskeletal and connective tissue disorders </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="568" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="569" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="570" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="571" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="572" pm="."><plain> Nervous system disorders </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="573" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="574" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="575" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="576" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="577" pm="."><plain> Respiratory, thoracic and mediastinal disorders </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="578" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="579" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="580" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="581" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="582" pm="."><plain> Skin and subcutaneous tissue disorders </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="583" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="584" pm="."><plain>0 </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="585" pm="."><plain>1 (0.8) </plain></SENT>
</text></td><td colspan="2" align="center"><text><SENT sid="586" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td colspan="9"><text><SENT sid="587" pm="."><plain>   </plain></SENT>
</text></td></tr><tr><td/><td colspan="4" align="center"><text><SENT sid="588" pm="."><plain>All causality </plain></SENT>
</text></td><td colspan="4" align="center"><text><SENT sid="589" pm="."><plain>Treatment-related </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="590" pm="."><plain>Extension phase </plain></SENT>
</text></td><td align="center"><text><SENT sid="591" pm="."><plain>C200 (n = 54) </plain></SENT>
</text></td><td align="center"><text><SENT sid="592" pm="."><plain>D75 (n = 55) </plain></SENT>
</text></td><td align="center"><text><SENT sid="593" pm="."><plain>C200/C400 (n = 53) </plain></SENT>
</text></td><td align="center"><text><SENT sid="594" pm="."><plain>D75/C400 (n = 54) </plain></SENT>
</text></td><td align="center"><text><SENT sid="595" pm="."><plain>C200 (n = 54) </plain></SENT>
</text></td><td align="center"><text><SENT sid="596" pm="."><plain>D75 (n = 55) </plain></SENT>
</text></td><td align="center"><text><SENT sid="597" pm="."><plain>C200/C400 (n = 53) </plain></SENT>
</text></td><td align="center"><text><SENT sid="598" pm="."><plain>D75/C400 (n = 54) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="599" pm="."><plain>Number of patients </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="600" pm="."><plain> With AEs </plain></SENT>
</text></td><td align="center"><text><SENT sid="601" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="602" pm="."><plain>6 (10.9) </plain></SENT>
</text></td><td align="center"><text><SENT sid="603" pm="."><plain>5 (9.4) </plain></SENT>
</text></td><td align="center"><text><SENT sid="604" pm="."><plain>6 (11.1) </plain></SENT>
</text></td><td align="center"><text><SENT sid="605" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="606" pm="."><plain>4 (7.3) </plain></SENT>
</text></td><td align="center"><text><SENT sid="607" pm="."><plain>3 (5.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="608" pm="."><plain>3 (5.6) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="609" pm="."><plain> Discontinued due to AEs </plain></SENT>
</text></td><td align="center"><text><SENT sid="610" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="611" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="612" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="613" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="614" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="615" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="616" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="617" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="618" pm="."><plain>Number of patients with AEs by system organ class </plain></SENT>
</text></td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td><text><SENT sid="619" pm="."><plain> Blood and lymphatic system disorders </plain></SENT>
</text></td><td align="center"><text><SENT sid="620" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="621" pm="."><plain>1 (1.8) </plain></SENT>
</text></td><td align="center"><text><SENT sid="622" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="623" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="624" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="625" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="626" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="627" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="628" pm="."><plain> Gastrointestinal disorders </plain></SENT>
</text></td><td align="center"><text><SENT sid="629" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="630" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="631" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="632" pm="."><plain>1 (1.9) </plain></SENT>
</text></td><td align="center"><text><SENT sid="633" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="634" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="635" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="636" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="637" pm="."><plain> Hepatobiliary disorders </plain></SENT>
</text></td><td align="center"><text><SENT sid="638" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="639" pm="."><plain>1 (1.8) </plain></SENT>
</text></td><td align="center"><text><SENT sid="640" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="641" pm="."><plain>1 (1.9) </plain></SENT>
</text></td><td align="center"><text><SENT sid="642" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="643" pm="."><plain>1 (1.8) </plain></SENT>
</text></td><td align="center"><text><SENT sid="644" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="645" pm="."><plain>1 (1.9) </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="646" pm="."><plain> Infections and infestations </plain></SENT>
</text></td><td align="center"><text><SENT sid="647" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="648" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="649" pm="."><plain>1 (1.9) </plain></SENT>
</text></td><td align="center"><text><SENT sid="650" pm="."><plain>2 (3.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="651" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="652" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="653" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="654" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td><text><SENT sid="655" pm="."><plain> Laboratory investigations† </plain></SENT>
</text></td><td align="center"><text><SENT sid="656" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="657" pm="."><plain>4 (7.3) </plain></SENT>
</text></td><td align="center"><text><SENT sid="658" pm="."><plain>4 (7.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="659" pm="."><plain>2 (3.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="660" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="661" pm="."><plain>3 (5.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="662" pm="."><plain>3 (5.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="663" pm="."><plain>2 (3.7) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>C200 = celecoxib 200 mg once daily during double-blind and extension phase; C200/C400 = celecoxib 200 mg once daily during double-blind phase and celecoxib 400 mg once daily during extension phase; D75 = diclofenac sustained release 75 mg once daily during double-blind and extension phase; D75/C400 = diclofenac sustained release 75 mg once daily during double-blind phase and celecoxib 400 mg once daily during extension phase.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblVIfnStar"><label>⁎</label><p>Patients were only counted once per treatment row; AEs occurring during the double-blind phase and up to 30 days after last dose (in double-blind phase) included. Values are presented as n (%).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblVIfnDagger"><label>†</label><p>Laboratory investigations include alanine aminotransferase increased, aspartate aminotransferase increased, red blood cells urine positive, transaminases increased, weight decreased, and white blood cell count decreased.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
